Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK(英語版), Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). “Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer”. N Engl J Med349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID12853587.
The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011). Dalteparin versus unfractionated heparin in critically ill patients. doi:10.1056/NEJMoa1014475.
Douketis J, Cook D, Meade M (2008). “Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin”. Arch Intern Med168 (16): 1805–1812. doi:10.1001/archinte.168.16.1805. PMID18779469.
nih.gov
pubmed.ncbi.nlm.nih.gov
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK(英語版), Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). “Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer”. N Engl J Med349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID12853587.
Douketis J, Cook D, Meade M (2008). “Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin”. Arch Intern Med168 (16): 1805–1812. doi:10.1001/archinte.168.16.1805. PMID18779469.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK(英語版), Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). “Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer”. N Engl J Med349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID12853587.